327 related articles for article (PubMed ID: 2096302)
1. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
2. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. II. Relationships between chemical structure and inhibition of PAF-induced human platelet activation.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1991; 3(2):225-37. PubMed ID: 1797154
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids.
Ostermann G; Hofmann B; Kertscher HP; Till U
Thromb Res; 1991 Feb; 61(3):261-9. PubMed ID: 2028445
[TBL] [Abstract][Full Text] [Related]
4. CIS-19, a novel platelet activating factor receptor antagonist: in vitro and in vivo studies.
Ko FN; Yu SM; Chen IS; Ishii H; Chang YL; Huang TF; Teng CM
Biochim Biophys Acta; 1993 Jan; 1175(2):225-31. PubMed ID: 8380343
[TBL] [Abstract][Full Text] [Related]
5. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
Terashita Z; Imura Y; Takatani M; Tsushima S; Nishikawa K
J Pharmacol Exp Ther; 1987 Jul; 242(1):263-8. PubMed ID: 3612533
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
[TBL] [Abstract][Full Text] [Related]
7. Effects of the synthetic ether phospholipid KO-286011 on cells and components of rabbit blood.
Hofmann B; Greiner J; Glusa E; Kertscher HP; Ostermann G
Haemostasis; 1991; 21(2):77-84. PubMed ID: 1959801
[TBL] [Abstract][Full Text] [Related]
8. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets.
Adnot S; Joseph D; Vargaftig BB
Agents Actions; 1987 Jun; 21(1-2):195-202. PubMed ID: 3115070
[TBL] [Abstract][Full Text] [Related]
9. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
10. Action of platelet-activating factor (PAF) antagonists on the bronchopulmonary effects of PAF in the guinea-pig.
Pons F; Touvay C; Lejeune V; Carré C; Vilain B; Broquet C; Mencia-Huerta JM; Braquet P
J Lipid Mediat; 1989; 1(6):329-40. PubMed ID: 2519901
[TBL] [Abstract][Full Text] [Related]
11. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
12. Effects of platelet activating factor antagonists on arachidonic acid-induced platelet aggregation and TXA2 formation.
Heinroth-Hoffmann I; Hauser A; Mest HJ
Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):181-2. PubMed ID: 2149184
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist.
Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K
Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of adrenaline-induced human platelet aggregation by the structurally related Paf antagonist Ro 19-3704.
Schattner M; Parini A; Fouque F; Vargaftig BB; Touqui L
Br J Pharmacol; 1989 Apr; 96(4):759-66. PubMed ID: 2787179
[TBL] [Abstract][Full Text] [Related]
17. 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine: an analogue of platelet-activating factor with partial agonist activity.
Grigoriadis G; Stewart AG
Br J Pharmacol; 1991 Sep; 104(1):171-7. PubMed ID: 1664761
[TBL] [Abstract][Full Text] [Related]
18. Alkyl and alkoxycarbonyl derivatives of ginkgolide B: synthesis and biological evaluation of PAF inhibitory activity.
Hu L; Chen Z; Xie Y; Jiang Y; Zhen H
Bioorg Med Chem; 2000 Jun; 8(6):1515-21. PubMed ID: 10896127
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PAF-induced tPA release by KO-286011.
Klöcking HP
Ann N Y Acad Sci; 1992 Dec; 667():202-3. PubMed ID: 1309038
[No Abstract] [Full Text] [Related]
20. PAF antagonism in vitro and in vivo by aglafoline from Aglaia elliptifolia Merr.
Ko FN; Wu TS; Liou MJ; Huang TF; Teng CM
Eur J Pharmacol; 1992 Jul; 218(1):129-35. PubMed ID: 1327822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]